Literature DB >> 27995619

Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.

J Gottlieb1,2, S Ingen-Housz-Oro1,2,3, M Alexandre2,4, S Grootenboer-Mignot2,5, F Aucouturier2,6, E Sbidian1,3,7, E Tancrede2,8, P Schneider2,8,9, E Regnier2,10, C Picard-Dahan2,11, E Begon12, C Pauwels13, K Cury2,14, S Hüe2,3,15, C Bernardeschi2,9, N Ortonne2,3,16, F Caux2,4,17, P Wolkenstein1,2,3, O Chosidow1,2,3,7, C Prost-Squarcioni2,4,17,18.   

Abstract

BACKGROUND: Linear IgA bullous dermatosis (LABD) is a clinically and immunologically heterogeneous, subepidermal, autoimmune bullous disease (AIBD), for which the long-term evolution is poorly described.
OBJECTIVES: To investigate the clinical and immunological characteristics, follow-up and prognostic factors of adult idiopathic LABD.
METHODS: This retrospective study, conducted in our AIBD referral centre, included adults, diagnosed between 1995 and 2012, with idiopathic LABD, defined as pure or predominant IgA deposits by direct immunofluorescence. Clinical, histological and immunological findings were collected from charts. Standard histology was systematically reviewed, and indirect immunofluorescence (IIF) on salt-split skin (SSS) and immunoblots (IBs) on amniotic membrane extracts using anti-IgA secondary antibodies were performed, when biopsies and sera obtained at diagnosis were available. Prognostic factors for complete remission (CR) were identified using univariate and multivariate analyses.
RESULTS: Of the 72 patients included (median age 54 years), 60% had mucous membrane (MM) involvement. IgA IIF on SSS was positive for 21 of 35 patients tested; 15 had epidermal and dermal labellings. Immunoelectron microscopy performed on the biopsies of 31 patients labelled lamina lucida (LL) (26%), lamina densa (23%), anchoring-fibril zone (AFz) (19%) and LL+AFz (23%). Of the 34 IgA IBs, 22 were positive, mostly for LAD-1/LABD97 (44%) and full-length BP180 (33%). The median follow-up was 39 months. Overall, 24 patients (36%) achieved sustained CR, 19 (29%) relapsed and 35% had chronic disease. CR was significantly associated with age > 70 years or no MM involvement. No prognostic immunological factor was identified.
CONCLUSIONS: Patients with LABD who are < 70 years old and have MM involvement are at risk for chronic evolution.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 27995619     DOI: 10.1111/bjd.15244

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

Authors:  Bethsabée Garel; Saskia Ingen-Housz-Oro; Daniele Afriat; Catherine Prost-Squarcioni; Florence Tétart; Benoit Bensaid; Corina Bara Passot; Marie Beylot-Barry; Vincent Descamps; Sophie Duvert-Lehembre; Sabine Grootenboer-Mignot; Géraldine Jeudy; Angèle Soria; Marie Blanche Valnet-Rabier; Annick Barbaud; Frédéric Caux; Bénédicte Lebrun-Vignes
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

2.  Vancomycin-induced linear IgA bullous dermatosis.

Authors:  Claire J Wiggins; Susan Y Chon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-26

3.  A 62-year-old man with new-onset bullae.

Authors:  August J Generoso; Jordana A Goldman; Alan H Wolff
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

4.  Vancomycin Mediates IgA Autoreactivity in Drug-Induced Linear IgA Bullous Dermatosis.

Authors:  Jun Yamagami; Yoshio Nakamura; Keisuke Nagao; Takeru Funakoshi; Hayato Takahashi; Akiko Tanikawa; Takahisa Hachiya; Toshiyuki Yamamoto; Akemi Ishida-Yamamoto; Toshihiro Tanaka; Noriki Fujimoto; Chikako Nishigori; Tetsuya Yoshida; Norito Ishii; Takashi Hashimoto; Masayuki Amagai
Journal:  J Invest Dermatol       Date:  2018-02-02       Impact factor: 8.551

5.  Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.

Authors:  Aniek Lamberts; H Ilona Euverman; Jorrit B Terra; Marcel F Jonkman; Barbara Horváth
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

6.  Linear IgA bullous dermatosis successfully treated with omalizumab: A case report.

Authors:  Nadine S Maalouf; Dominique Hanna
Journal:  JAAD Case Rep       Date:  2019-10-24

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.